First In-Human Investigator-Initiated Clinical Trial to Launch for Refractory Prostate Cancer Patients: Novel Alpha Therapy Targets Prostate-Specific Membrane Antigen

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models. This will be a world-first in-human clinical trial with [At-211] PSMA-5.

Login Or Register To Read Full Story